Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Valve Hemodynamics by Valve Size and 1-Year Survival Following Implantation of the Portico Valve in the Multicenter CONFIDENCE Registry

H. Möllmann, A. Linke, L. Nombela-Franco, M. Sluka, J. Francisco Oteo Dominguez, M. Montorfano, WK. Kim, M. Arnold, M. Vasa-Nicotera, S. Fichtlscherer, L. Conradi, A. Camuglia, F. Bedogni, K. Kohli, G. Manoharan

. 2024 ; 8 (1) : 100226. [pub] 20231111

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006100

BACKGROUND: The CONtrolled delivery For ImproveD outcomEs with cliNiCal Evidence registry was initiated to characterize the clinical safety and device performance from experienced transcatheter aortic valve implantation (TAVI) centers in Europe and Australia that use the Portico valve to treat patients with severe aortic stenosis. We herein report for the first time the valve performance at 30-day across all implanted valve sizes and the 1-year survival from this registry. METHODS: This was a prospective, multicenter, single-arm observational clinical investigation of patients clinically indicated for implantation of a Portico valve in experienced TAVI centers. Patients were treated with a commercially available valve (size 23, 25, 27, or 29 mm) using either the first-generation delivery system (DS) (n = 501) or the second-generation (FlexNav) DS (n = 500). Adverse events were adjudicated by an independent clinical events committee according to Valve Academic Research Consortium-2 criteria. Echocardiographic outcomes were assessed at 30 days by an independent core laboratory, and a survival check was performed at 1 year. RESULTS: We enrolled 1001 patients (82.0 years, 62.5% female, 63.7% New York Heart Association functional class III/IV at baseline) from 27 clinical sites in 8 countries across Europe and one site in Australia. Implantation of a single valve was successful in 97.5% of subjects. Valve hemodynamics at 30 days were substantially improved relative to baseline, with large aortic valve areas and low mean gradients across all implanted valve sizes (aortic valve areas were 1.7 ± 0.4, 1.7 ± 0.5, 1.8 ± 0.5, and 2.0 ± 0.5 cm2, and mean gradients were 7.0 ± 2.7, 7.5 ± 4.7, 7.3 ± 3.3, and 6.4 ± 3.3 mmHg for 23, 25, 27, and 29 mm valve sizes, respectively). Across all implanted valve sizes, most patients (77.1%) had no patient-prosthesis mismatch. Death from any cause within 1 year occurred in 13.7% of the patients in the first-generation DS group as compared with 11.0% in the second-generation DS group (p = 0.2). CONCLUSIONS: The Portico valve demonstrated excellent hemodynamic performance across all valve sizes in a large cohort of subjects implanted in experienced TAVI centers. One-year survival rates were favorable when using both the first-generation and second-generation (FlexNav) DSs in this high-risk cohort. CLINICALTRIALSGOV IDENTIFIER: NCT03752866.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006100
003      
CZ-PrNML
005      
20240412130933.0
007      
ta
008      
240405s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.shj.2023.100226 $2 doi
035    __
$a (PubMed)38283573
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Möllmann, Helge $u Department of Cardiology, St. Johannes Hospital, Dortmund, Germany
245    10
$a Valve Hemodynamics by Valve Size and 1-Year Survival Following Implantation of the Portico Valve in the Multicenter CONFIDENCE Registry / $c H. Möllmann, A. Linke, L. Nombela-Franco, M. Sluka, J. Francisco Oteo Dominguez, M. Montorfano, WK. Kim, M. Arnold, M. Vasa-Nicotera, S. Fichtlscherer, L. Conradi, A. Camuglia, F. Bedogni, K. Kohli, G. Manoharan
520    9_
$a BACKGROUND: The CONtrolled delivery For ImproveD outcomEs with cliNiCal Evidence registry was initiated to characterize the clinical safety and device performance from experienced transcatheter aortic valve implantation (TAVI) centers in Europe and Australia that use the Portico valve to treat patients with severe aortic stenosis. We herein report for the first time the valve performance at 30-day across all implanted valve sizes and the 1-year survival from this registry. METHODS: This was a prospective, multicenter, single-arm observational clinical investigation of patients clinically indicated for implantation of a Portico valve in experienced TAVI centers. Patients were treated with a commercially available valve (size 23, 25, 27, or 29 mm) using either the first-generation delivery system (DS) (n = 501) or the second-generation (FlexNav) DS (n = 500). Adverse events were adjudicated by an independent clinical events committee according to Valve Academic Research Consortium-2 criteria. Echocardiographic outcomes were assessed at 30 days by an independent core laboratory, and a survival check was performed at 1 year. RESULTS: We enrolled 1001 patients (82.0 years, 62.5% female, 63.7% New York Heart Association functional class III/IV at baseline) from 27 clinical sites in 8 countries across Europe and one site in Australia. Implantation of a single valve was successful in 97.5% of subjects. Valve hemodynamics at 30 days were substantially improved relative to baseline, with large aortic valve areas and low mean gradients across all implanted valve sizes (aortic valve areas were 1.7 ± 0.4, 1.7 ± 0.5, 1.8 ± 0.5, and 2.0 ± 0.5 cm2, and mean gradients were 7.0 ± 2.7, 7.5 ± 4.7, 7.3 ± 3.3, and 6.4 ± 3.3 mmHg for 23, 25, 27, and 29 mm valve sizes, respectively). Across all implanted valve sizes, most patients (77.1%) had no patient-prosthesis mismatch. Death from any cause within 1 year occurred in 13.7% of the patients in the first-generation DS group as compared with 11.0% in the second-generation DS group (p = 0.2). CONCLUSIONS: The Portico valve demonstrated excellent hemodynamic performance across all valve sizes in a large cohort of subjects implanted in experienced TAVI centers. One-year survival rates were favorable when using both the first-generation and second-generation (FlexNav) DSs in this high-risk cohort. CLINICALTRIALSGOV IDENTIFIER: NCT03752866.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Linke, Axel $u Department of Internal Medicine/Cardiology, University Hospital of the Technical University of Dresden, Heart Center Dresden, Dresden, Germany
700    1_
$a Nombela-Franco, Luis $u Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain
700    1_
$a Sluka, Martin $u Department of Medicine-Cardiology, University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Francisco Oteo Dominguez, Juan $u Cardiology Department, Puerta de Hierro Hospital, Madrid, Spain
700    1_
$a Montorfano, Matteo $u Interventional Cardiology Unit IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Kim, Won-Keun $u Kerckhoff Heart and Thorax Centre, Bad Nauheim, Germany
700    1_
$a Arnold, Martin $u Department of Cardiology, Friedrich-Alexander-Universität Erlangen Nuremberg, Erlangen, Germany
700    1_
$a Vasa-Nicotera, Mariuca $u Department of Cardiology, University Hospital of the Johann Wolfgang Goethe University Frankfurt, Frankfurt, Germany
700    1_
$a Fichtlscherer, Stephan $u Department of Cardiology, University Hospital of the Johann Wolfgang Goethe University Frankfurt, Frankfurt, Germany
700    1_
$a Conradi, Lenard $u Department of Cardiovascular Surgery, University Heart and Vascular Center, Hamburg, Germany
700    1_
$a Camuglia, Anthony $u University of Queensland, Brisbane, Australia $u The Wesley Hospital, Brisbane, Australia
700    1_
$a Bedogni, Francesco $u IRCCS Policlinico San Donato, Milan, Italy
700    1_
$a Kohli, Keshav $u Abbott Laboratories, Santa Clara, California, USA
700    1_
$a Manoharan, Ganesh $u Department of Cardiology, Royal Victoria Hospital, Belfast, UK
773    0_
$w MED00211269 $t Structural heart $x 2474-8714 $g Roč. 8, č. 1 (2024), s. 100226
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38283573 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412130925 $b ABA008
999    __
$a ok $b bmc $g 2076126 $s 1215862
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 8 $c 1 $d 100226 $e 20231111 $i 2474-8714 $m Structural heart $n Struct. heart $x MED00211269
LZP    __
$a Pubmed-20240405

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace